Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 10348739.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Vaccines based on preferential expression of bacterial antigens during human infection have not been described. Staphylococcus aureus synthesized poly-N-succinyl beta-1-6 glucosamine (PNSG) as a surface polysaccharide during human and animal infection, but few strains expressed PNSG in vitro. All S. aureus strains examined carried genes for PNSG synthesis. Immunization protected mice against kidney infections and death from strains that produced little PNSG in vitro. Nonimmune infected animals made antibody to PNSG, but serial in vitro cultures of kidney isolates yielded mostly cells that did not produce PNSG. PNSG is a candidate for use in a vaccine to protect against S. aureus infection.
Medical subject headings
- Antibodies, Bacterial
- Polysaccharides, Bacterial
- Staphylococcal Infections
- Staphylococcal Vaccines
- Staphylococcus aureus